Capricor療法 CAPR 深 滬
已收盤 02-06 16:00:00 美东时间
24.72
+1.690
+7.34%
華盛通- 最 高25.21
- 今 開23.36
- 成交量 113.11万股
- 最 低 23.23
- 昨 收 23.03
- 總市值 13.45亿
- 52周最高 40.37
- 市盈率 靜 --
- 換手率 2.08%
- 52周最低 4.30
- 委 比 99.17%
- 總股本 5439.93万
- 歷史最高 171.50
- 量 比 1.13
- 振 幅 8.60%
- 歷史最低 0.88
- 每 手 1
- 風險率 6.97%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Capricor Therapeutics stellt neue Pipeline-Strategien und Fortschritte bei Duchenne-Muskeldystrophie-Therapien vor
Capricor Therapeutics stellt neue Pipeline-Strategien und Fortschritte bei Duchenne-Muskeldystrophie-Therapien vor Capricor Therapeutics Inc. hat eine neue Unternehmenspräsentation veröffentlicht. Das Unternehmen informiert darin über den aktuellen Stand des Deramiocel-Programms für Duchenne-Muskeld
02-05 22:44
Capricor Therapeutics Unveils Investor Presentation Highlighting Duchenne Program and Exosome Platform
Capricor Therapeutics Unveils Investor Presentation Highlighting Duchenne Program and Exosome Platform Capricor Therapeutics Inc. (Nasdaq: CAPR) has released a new investor presentation detailing updates on its lead program, deramiocel, for the treatment of Duchenne muscular dystrophy (DMD). The pre
02-05 22:44
Capricor Therapeutics Announces FDA's Request HOPE-3 Clinical Study Report As Part Of Ongoing Biologics License Application Review Process
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today provided a regulatory update regarding its Biologics
01-20 22:20
Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA Following FDA Review of HOPE-3 Topline Data
Capricor Therapeutics has provided regulatory updates on its Biologics License Application (BLA) for Deramiocel, a cell therapy for Duchenne muscular dystrophy (DMD). The FDA has requested the full HOPE-3 clinical study report (CSR) and supporting data to address the Complete Response Letter (CRL). The company plans to submit the requested materials in February 2026, aiming to support continued FDA review and potentially secure a new PDUFA target...
01-20 14:15
美股周涨跌榜 | 脑再生科技涨超120%，马斯克“量产预告”催化脑机概念行情；Alumis周涨近120%
ANPA周涨近300%，公司获私募大额股份认购；脑再生科技涨超120%，马斯克“量产预告”催化脑机概念行情；Alumis周涨近120%，治疗银屑病新药临床成功>>
01-10 06:27
美股大行评级 | 潜在涨幅113%！麦格理首予小马智行“跑赢大市"评级目标价29美元；Roth Capital下调好市多至"卖出"，目标价从906美元降至769美元
今日重点评级关注：HC Wainwright & Co.：维持BioCryst Pharma"买入"评级，目标价从30美元升至32美元；TD Cowen：上调Milestone Pharmaceuticals评级至"买入"，目标价8美元
2025-12-16 09:36
B. Riley Securities Reiterates Buy on Capricor Therapeutics, Raises Price Target to $50
B. Riley Securities analyst Madison El-Saadi reiterates Capricor Therapeutics (NASDAQ:CAPR) with a Buy and raises the price target from $21 to $50.
2025-12-16 00:48
美股大行评级 | 超配！大摩上调回声星通信评级；汽车地带、CBRL、金宝汤、家得宝等遭多家大行下调目标价
今日重点评级关注：Ascendiant Capital：维持Lucid Diagnostics"买入"评级，目标价从8美元升至8.25美元；Ascendiant Capital：维持Aytu BioPharma"买入"评级，目标价从12.5美元升至13美元
2025-12-11 10:33
What Does the Market Think About Capricor Therapeutics Inc?
Capricor Therapeutics Inc's (NYSE:CAPR) short interest as a percent of float ha...
2025-12-11 01:00
美股大行评级 | 潜在涨幅2566.67%！Ascendiant Capital上调GRI Bio目标价至36美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持GRI Bio"买入"评级，目标价从35美元升至36美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从7.75美元升至8美元
2025-12-09 10:32
